Drug profile · INN
olutasidenib
REZLIDHIA
olutasidenib (REZLIDHIA) is a isocitrate dehydrogenase [nadp] cytoplasmic inhibitor. Associated with RIGEL PHARMACEUTICALS INC. Route of administration: oral. Current US regulatory status: approved.
Drug details — olutasidenib
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 20
- Programs
- 9
- Data quality
- 0.89
Quick answer
olutasidenib (REZLIDHIA) is a isocitrate dehydrogenase [nadp] cytoplasmic inhibitor. Associated with RIGEL PHARMACEUTICALS INC. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
Primary target: Isocitrate dehydrogenase [NADP] cytoplasmic
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12043620
Benzazole compounds and methods for making and using the compounds
granted -
US 11939317
Amide compounds and method for making and using
granted -
US 11827628
Compositions and methods for inhibition of the JAK pathway
granted -
US 11667611
Compositions and methods for inhibition of the JAK pathway
granted -
US 11530194
Amide compounds and method for making and using
granted -
US 11524955
2,4-diamino-pyrimidine compounds and method for making and using the compounds
granted -
US 11370808
Pyrazole compounds and methods for making and using the compounds
granted -
US 11299486
Benzazole compounds and methods for making and using the compounds
granted -
US 11279686
Nrf2 activating compounds and uses thereof
granted -
US 11230554
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
granted -
US 11220496
Compounds and method for treating autoimmune diseases
granted -
US 11198689
Compositions and methods for inhibition of the JAK pathway
granted -
US 11174251
Compositions and methods for inhibition of the JAK pathway
granted -
US 11174246
Direct AMPK activators
granted -
US 11129819
Fumarate analogs and uses thereof
granted -
US 11007193
2,4-pyrimidinediamine compounds and their uses
granted -
US 10947216
Amide compounds and method for making and using
granted -
US 10941135
Nrf2 activating compounds and uses thereof
granted -
US 10941134
AMPK-activating heterocyclic compounds and methods for using the same
granted -
US 10889562
Prodrugs of Nrf2 activating compounds and uses thereof
granted
Frequently asked questions
What is olutasidenib?
olutasidenib (REZLIDHIA) is a isocitrate dehydrogenase [nadp] cytoplasmic inhibitor. Associated with RIGEL PHARMACEUTICALS INC. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for olutasidenib?
REZLIDHIA is a marketed brand name for olutasidenib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of olutasidenib?
olutasidenib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.